ArticleAmerican journal of translational research2025
MiR-193-3p suppresses phenotypic switching in vascular smooth muscle cells by regulating IGF2 during in-stent restenosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysregulated proliferation and migration of vascular smooth muscle cells (VSMCs) are central to the development of in-stent restenosis (ISR). Clinically, regulating VSMC phenotype during proliferation and migration presents a potential therapeutic approach to prevent IRS. However, the role of miR-193-3p in ISR pathogenesis remains largely uncharacterized.
objectiveTo investigate the role of miR-193-3p in ISR pathogenesis, focusing on the molecular mechanisms mediated by miR-193-3p, specifically the miR-193-3p/insulin-like growth factor-2 (IGF2) axis in regulating ISR.
methodsSerum levels of miR-193-3p were quantified in ISR patients and healthy controls using quantitative real-time polymerase chain reaction (qPCR). miR-193-3p mimic transfection in VSMCs was confirmed by qPCR. The phenotypic switching of VSMCs was assessed via qPCR and western blot. Proliferative and migratory activities were evaluated using CCK-8 and Transwell assays, respectively. IGF2 levels in VSMCs were assessed using qPCR and WB assays.
resultsSerum levels of miR-193-3p were significantly reduced in ISR patients compared to healthy controls (P < 0.05). Overexpressing miR-193-3p markedly suppressed VSMC proliferation and migration (P < 0.05), while upregulating differentiation-associated VSMC markers at both mRNA and protein levels (P < 0.05). Mechanistically, IGF2 was identified as a direct target of miR-193-3p. Additionally, miR-193-3p expression was elevated in VSMCs following IGF2 stimulation (P < 0.05), and this upregulation counteracted IGF2-induced proliferative and migratory activity (P < 0.05).
conclusionsThese findings suggest the miR-193-3p may serve as a potential biomarker for ISR and that targeting the miR-193-3p/IGF2 axis could be a promising strategy for managing ISR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.